Organic Chemical
Arrowhead’s Plozasiran Projected to Surpass $700M in Sales by 2032, Addressing Major Unmet Needs in Dyslipidemia Treatment
Arrowhead Pharmaceuticals, Plozasiran, Dyslipidemia, GlobalData, Sales Forecast, $700M, 2032, Unmet Needs, Triglyceride Reduction, APOC3 Targeting, SHTG (Severe Hypertriglyceridemia), FCS (Familial Chylomicronemia Syndrome), Mixed Dyslipidemia
Intra-Cellular’s Caplyta Shows Promising Results in Major Depressive Disorder Study
Intra-Cellular Therapies, Caplyta (lumateperone), Major Depressive Disorder (MDD), Positive clinical trial results, Study 501, Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression Scale, Adjunctive therapy, Potential blockbuster label expansion
Boehringer Ingelheim Leverages Late-Stage Pipeline for 25 New Launches over the Next Decade
Boehringer Ingelheim, Late-stage pipeline, 25 new launches, Decade, Jardiance, Heart failure approvals, Ofev, Pipeline expansion, Management reshuffle
Novartis’ Fabhalta (Iptacopan) Receives FDA Priority Review for IgA Nephropathy (IgAN) Treatment
Novartis, Fabhalta, Iptacopan, IgA Nephropathy (IgAN), FDA Priority Review, Phase 3 Data
Record-Breaking 323 Medications in Active Shortage in US, ASHP Reports
Drug shortages, US, Record-high, American Society of Health-System Pharmacists (ASHP), 323 medications, Active shortages, Generic sterile injectable medications, Cancer chemotherapy drugs, ADHD medications, Adderall, Drug Enforcement Administration (DEA), Drug supply chains, Policy recommendations
Novartis Secures $1B Protein Degrader Deal with Arvinas and Initiates MorphoSys Tender Offer
Novartis, Arvinas, Protein Degrader Deal, PROTAC® Androgen Receptor Degrader, MorphoSys Tender Offer
Novartis Announces 680 Layoffs in Development Group Amid Corporate Restructuring
Novartis, Layoffs, Development Group, Corporate Restructuring, 680 Jobs, Switzerland, United States, Pharmaceutical Industry
AstraZeneca’s Lynparza Demonstrates Nearly 50% Response in Advanced Breast Cancer Patients: #AACR24 Update
AstraZeneca, Lynparza (olaparib), PARP inhibitor, Advanced breast cancer, 50% response rate, AACR24
Expansion of Pluvicto Use Sought by Novartis Following Positive Prostate Cancer Study Update
Novartis, Pluvicto, Broader use, Prostate cancer, PSMAfore trial, Radiographic progression-free survival (rPFS), Metastatic castration-resistant prostate cancer (mCRPC)
Sanofi Settles 4,000 Zantac Cancer Lawsuits, Faces Delaware Claims
Sanofi, Zantac, Cancer Lawsuits, Settlement, Delaware Claims, 4/000 Lawsuits, Delaware Superior Court, Daubert Ruling